Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
MDA19 has potential for alleviating neuropathic pain without producing adverse effects in the central nervous system
3-benzodioxol-5-yl)ethyl]-3-(diphenylmethoxy)piperidine
Only mutant p53-bearing tumors in the ReACp53-treated mice cohorts are 80-90% smaller in weight than the control cohort
dose-dependent exposure and modulation of the pharmacodynamic marker p-ERK is observed in the xenografts
5-HT2 antagonist 1 is a potent antagonist of 5-HT2 receptor
NVS-CECR2-1 rlukast MDA19 has potential for alleviatingNVS CECR2 1, a non BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS CECR2 1 binds to CECR2 BRD with high affinity (IC50=47 nM; KD=80 nM). NVS CECR2 1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2 independent mechanism. Product information CAS Number: 1992047 61 6 Molecular Weight: 495. 68
US$ 256.98
US$ 171.97
US$ 79.95
US$ 13.95
US$ 1291.47
US$ 946.98